Work

Personalized Irinotecan Treatment: the patient matters

Year: 2011
Type: dissertation
Abstract: In the early sixties of the last century, camptothecin (CPT) was isolated from the Chinese\\nplant Camptotheca acuminata (Nyssaceae family), and was found to be a very potent\\nantitumor agent in vitro. However, its clinical development was hindered by a relatively\\nlimited clinical activity and severe and unpredictable toxicities, most problematic being\\nhemorrhagic cystitis and enteritis. These turned out to be partially related to the poor\\nhydrophilicity of the drug and the initial administration of camptothecin in the inactive\\ncarboxylate form. Once the mechanism of action of camptothecin was discovered,\\nthere was renewed interest in the drug. Eff orts were made to develop water-soluble\\ncamptothecin analogues with improved antitumor activity and decreased toxicity. Irinotecan,\\nalso known as CPT-11, was developed as a water-soluble prodrug of SN-38, a very\\npotent camptothecin analogue, which has a 100-1000 fold higher cytotoxic activity\\nin vitro than the parent compound. Camptothecins, including irinotecan and SN-38,\\ninhibit the enzyme topoisomerase-I by binding to it and forming a stable complex\\nbetween topoisomerase-I and DNA. This induces single-strand breaks in chromosomal\\nDNA, ultimately leading to cytotoxicity and apoptosis.
Author: Bol, Jessica
Language: English
Open Access status: green
OpenAlex ID: W7033294579
Cites: 261
Cited by:
Related to: 10